Emergent FFP for Angioedema?

Why Would the ER Order FFP for a Patient With a Swollen Tongue?

You get a call from the Emergency Department:

“We need plasma now. The patient's tongue and face are swelling and we're worried about the airway.”

The patient has no blood type on file.

You may be thinking: Why the hell are we giving plasma? They aren't bleeding. Their INR isn't elevated. They're not in massive transfusion.

Depending on your institution's emergency plasma policy, you may end up thawing group AB plasma or another plasma product approved by your facility for emergency use before the patient's ABO type is known.

So what exactly is happening?

One possibility is ACE inhibitor-induced angioedema.

And in severe cases, fresh frozen plasma has historically been used as an unusual rescue treatment.

ACE Inhibitors and Angioedema

Angiotensin-converting enzyme inhibitors—such as lisinopril, enalapril, ramipril, and others—are widely used to treat hypertension, heart failure, and other cardiovascular conditions.

One uncommon but potentially life-threatening adverse effect is angioedema, particularly involving the lips, tongue, face, pharynx, and larynx.

Importantly, this is usually not an allergic, histamine-mediated reaction.

It is primarily a bradykinin-mediated reaction.

ACE inhibitor-associated angioedema can occur at essentially any point during therapy; FDA labeling for ACE inhibitors specifically warns that angioedema may develop at any time during treatment.

What Does ACE Normally Do?

Angiotensin-converting enzyme has more than one job.

Most people learn ACE as the enzyme that converts:

Angiotensin I → Angiotensin II

That explains why inhibiting ACE lowers blood pressure.

But ACE is also known as kininase II, because it helps degrade bradykinin.

Bradykinin is not an enzyme. It is a small vasoactive peptide.

Among other effects, bradykinin causes:

• vasodilation

• increased vascular permeability

• movement of fluid from the intravascular space into surrounding tissues

Normally, ACE helps break bradykinin down.

Give someone an ACE inhibitor and that degradation pathway becomes less effective. In susceptible individuals, excessive bradykinin activity can develop and produce profound localized tissue edema.

Why Does the Tongue Swell?

Bradykinin increases vascular permeability.

Fluid moves from the vasculature into the interstitial tissues, producing the characteristic nonpitting swelling of angioedema.

When that swelling involves an arm or a lip, it may be uncomfortable.

When it involves the tongue, floor of the mouth, hypopharynx, or larynx, it can become a completely different problem.

The airway can progressively narrow until the patient can no longer ventilate adequately.

Patients with anterior tongue swelling, voice changes, drooling, respiratory distress, or deeper airway involvement are at greater risk of needing airway intervention. ACE inhibitor-associated upper-airway angioedema can therefore become a true airway emergency.

And once the airway is badly distorted by edema, intubation may become considerably more difficult.

That means the most important treatment in severe ACE inhibitor angioedema is not a bag of plasma.

It is recognizing a threatened airway early and securing it when necessary.

Why Don't Benadryl, Steroids, and Epinephrine Fix It?

This is where ACE inhibitor angioedema differs from classic allergic angioedema.

In anaphylaxis or other mast-cell-mediated reactions, histamine is an important driver. Epinephrine, antihistamines, and corticosteroids therefore make physiologic sense.

ACE inhibitor angioedema is different.

The principal mediator is bradykinin, not histamine.

As a result, antihistamines and corticosteroids generally do not directly reverse the underlying mechanism, and epinephrine may also have limited effect on the edema itself.

A published case series of patients with progressive ACE inhibitor angioedema described patients who continued to worsen despite epinephrine, antihistamines, and corticosteroids before receiving FFP.

Those medications may still be given initially when the cause of angioedema is uncertain—because anaphylaxis is obviously something you do not want to miss—but lack of response can be another clue that the process is bradykinin-mediated.

And IVIG is not a standard treatment for ACE inhibitor angioedema, so I would remove that from the old version entirely.

So Why Would FFP Help?

Now we finally get back to the blood bank.

Fresh frozen plasma contains a huge collection of normal human plasma proteins and enzymes.

Among them is angiotensin-converting enzyme—kininase II.

Remember what the patient's ACE inhibitor has done:

ACE activity ↓ → bradykinin degradation ↓ → bradykinin activity ↑ → vascular permeability ↑ → angioedema

The proposed reasoning behind FFP is therefore surprisingly straightforward.

By transfusing donor plasma, you introduce functional ACE and other plasma enzymes capable of metabolizing bradykinin.

That may temporarily restore enough bradykinin-degrading capacity to reduce the excessive bradykinin activity and allow the edema to begin resolving.

There are published reports of striking improvement after FFP administration. A seven-patient case series described progressive ACE inhibitor-associated angioedema that improved in temporal association with FFP after conventional treatments had failed. Earlier reports likewise described improvement in otherwise resistant, life-threatening ACE inhibitor angioedema and proposed replacement of kininase II as the mechanism.

That's why you may occasionally receive the bizarre-sounding request:

“I need plasma for angioedema.”

They aren't trying to replace coagulation factors.

They're essentially trying to replace bradykinin-degrading activity.

Does FFP Definitely Work?

Here's where things get less satisfying.

No.

The evidence for FFP in ACE inhibitor angioedema is largely composed of case reports and case series rather than large randomized controlled trials.

That creates a major problem when interpreting reports of rapid improvement: ACE inhibitor angioedema often eventually resolves on its own, so improvement shortly after plasma administration does not necessarily prove that the plasma caused the improvement.

The seven-patient series, for example, showed a temporal association between FFP and improvement—but it was not a randomized trial with an untreated control group.

FFP is also not uniformly effective. Differences in ACE activity between donor plasma units have even been proposed as one possible explanation for variable responses.

And there is an additional wrinkle:

Plasma doesn't contain only enzymes that destroy bradykinin.

It also contains components of the kallikrein-kinin system from which bradykinin can be generated.

Rare cases of worsening angioedema after FFP have therefore been reported.

So FFP should not be thought of as the transfusion-medicine equivalent of naloxone:

Give plasma → bradykinin disappears → problem solved.

The biology is considerably messier than that.

What About Icatibant and Other Bradykinin-Targeted Drugs?

Several medications developed for hereditary angioedema target the same pathway and have therefore been investigated for ACE inhibitor angioedema.

Icatibant, for example, blocks the bradykinin B2 receptor.

An early randomized trial suggested faster resolution with icatibant, but a subsequent larger multicenter randomized controlled trial involving 121 patients found no improvement over placebo in time to discharge or symptom relief.

C1 esterase inhibitor concentrates, kallikrein inhibitors, and other approaches have also been studied or used off-label, but the evidence for ACE inhibitor-associated angioedema has been considerably less definitive than it is for hereditary angioedema.

The FDA-approved indications for drugs such as icatibant and ecallantide are for hereditary angioedema, not ACE inhibitor-induced angioedema.

That is one reason FFP can still occasionally appear in emergency treatment protocols despite the limited evidence: it is widely available in hospitals and has a plausible mechanism of action.

Plasma Isn't Harmless Either

It's also important not to treat FFP like a benign drug simply because the blood bank has a freezer full of it.

Plasma transfusion carries the same important risks it carries in any other setting, including:

• allergic and anaphylactic reactions

• transfusion-associated circulatory overload (TACO)

• transfusion-related acute lung injury (TRALI)

• ABO-related hemolysis if incompatible plasma is transfused

• citrate-related complications

• infectious risk, although modern donor screening and testing make transmission uncommon

FDA plasma labeling continues to list these transfusion-associated risks.

That matters particularly in a patient whose respiratory status may already be precarious.

What Blood Type of Plasma Do You Give?

Historically, the obvious emergency choice for a patient whose ABO type is unknown was group AB plasma, because AB plasma contains neither anti-A nor anti-B.

So the original scenario of thawing AB FFP is perfectly plausible.

However, modern emergency plasma practice is somewhat more flexible.

Some institutions use appropriately selected group A plasma with low-titer anti-B when the recipient's ABO type is not yet known, particularly because group AB plasma is relatively scarce. Current FDA-approved emergency plasma products even include both AB and low-titer group A options for use before the patient's ABO type has been determined.

Exactly what your blood bank issues will depend on its validated emergency plasma policy.

The Blood Bank Perspective

ACE inhibitor angioedema is one of those conditions that can generate a blood-product request that initially makes absolutely no sense.

The patient isn't hemorrhaging.

They don't necessarily have a coagulopathy.

They don't need factor replacement.

They're receiving plasma because something in the plasma itself may function as a drug.

Donor plasma contains functional ACE and other components of the bradykinin metabolism system. By restoring some bradykinin-degrading activity, FFP may help terminate severe ACE inhibitor-associated angioedema in selected patients.

But the important qualifiers are:

FFP is an off-label rescue therapy.

The clinical evidence is limited.

Response is not guaranteed.

Plasma itself carries meaningful transfusion risks.

And most importantly:

If the tongue and upper airway are rapidly swelling, plasma is not a substitute for airway management.

The weird unit of AB plasma you're rapidly thawing in the blood bank may help.

But the anesthesiologist standing beside the patient with an airway cart may be considerably more important.